Related Experiment Video
Updated: Jun 21, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal Denervation for Hypertension: The Current Landscape and Future Directions
Brian Fulton1, Jay Giri1,2, Florian Rader3
1Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Insights
Renal denervation therapy, using radiofrequency or ultrasound to ablate renal nerves, is now FDA-approved for uncontrolled hypertension. This adjunctive treatment offers a new option for managing high blood pressure and reducing cardiovascular risk.
Area of Science:
- Cardiology
- Nephrology
- Medical Devices
Background:
- Hypertension affects 47% of US adults, with over 40% having uncontrolled blood pressure, contributing significantly to cardiovascular morbidity and mortality.
- Renal denervation has emerged as a promising adjunctive therapy, with recent randomized controlled trials demonstrating its safety and efficacy.
Discussion:
- Two renal denervation devices utilizing radiofrequency or ultrasound energy have received US Food and Drug Administration (FDA) approval.
- These devices target perivascular sympathetic nerves in renal arteries to lower blood pressure.
Key Insights:
- The FDA approval marks a significant milestone for renal denervation technology in the United States.
- Evidence supports renal denervation as an effective adjunctive treatment for resistant hypertension.
Outlook:
- The post-FDA approval landscape presents ongoing discussions regarding the technology's optimal applications and integration into clinical practice.
- Reimbursement strategies and long-term outcomes will be critical for widespread adoption and patient access.
Abstract:
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the US population; however, recent estimates suggest that over 40% continue to have uncontrolled HTN. In the past decade, multiple placebo-controlled randomized studies have shown the safety and efficacy of renal denervation as an adjunctive therapy, culminating in the recent approval of two devices by the US Food and Drug Administration (FDA). These devices use either radiofrequency or ultrasound energies to ablate the perivascular sympathetic nerves in the renal arteries and have been shown to reduce blood pressure. In this immediate post-FDA approval era, there are still multiple issues regarding the future of the technology in its applications and reimbursement landscapes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:18Neural Regulation of Blood Pressure
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
01:18Hypertension and Regulation of Blood Pressure
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:23Antihypertensive Drugs: Vasodilators